Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented

BMC Women's Health

Volumn 14, Issue 1, 2014, Pages

  Rathod, Sujit D ^a,b   Buffler, Patricia A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; HUMAN; INCIDENCE; MORBIDITY; POPULATION; RECURRENT INFECTION; VAGINA CANDIDIASIS;

CANDIDIASIS, VULVOVAGINAL; DOCUMENTATION; FEMALE; HUMANS; INCIDENCE; PERIODICALS AS TOPIC; RESEARCH REPORT;

EID: 84897945373     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-14-43     Document Type: Article

References (78)

1. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA 2004, 291:1368. 10.1001/jama.291.11.1368, 15026404.
2. Hurley R. Inveterate vaginal thrush. Practitioner 1975, 215:753.
3. Foxman B, Barlow R, D'arcy H, Gillespie B, Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis 2000, 27:230-235. 10.1097/00007435-200004000-00009, 10782746.
4. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, Reed BD, Summers PR. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998, 178:203-211. 10.1016/S0002-9378(98)80001-X, 9500475.
5. Achkar JM, Fries BC. Candida infections of the genitourinary tract. Clin Microbiol Rev 2010, 23:253-273. 10.1128/CMR.00076-09, 2863365, 20375352.
6. Ahmad A, Khan AU. Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 2009, 144:68-71. 10.1016/j.ejogrb.2008.12.020, 19261369.
7. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol 1998, 92:757-765. 10.1016/S0029-7844(98)00264-6, 9794664.
8. Eckert LO. Acute vulvovaginitis. NEJM 2006, 355:1244-1252. 10.1056/NEJMcp053720, 16990387.
9. Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol 2012, 120:1407-1414.
10. Ferrer J. Vaginal candidosis: epidemiological and etiological factors. Int J Gynecol Obstet 2000, 71:21-27.
11. Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: A mycological perspective. Crit Rev Microbiol 2011, 37:250-261. 10.3109/1040841X.2011.576332, 21599498.
12. Nyirjesy P, Seeney SM, Terry Grody MH, Jordan CA, Buckley HR. Chronic fungal vaginitis: the value of cultures. Am J Obstet Gynecol 1995, 173:820-823. 10.1016/0002-9378(95)90347-X, 7573250.
13. Reed BD. Risk factors for Candida vulvovaginitis. Obstet Gynecol 1992, 47:551.
14. Sobel JD. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 1985, 152(7 Pt 2):924.
15. Xu J, Sobel JD. Antibiotic-associated vulvovaginal candidiasis. Curr Infect Dis Rep 2003, 5:481-487. 10.1007/s11908-003-0091-x, 14642189.
16. Mundy RD, Cormack B. Expression of Candida glabrata adhesins after exposure to chemical preservatives. J Infect Dis 1891-1898, 2009:199.
17. Rodgers C, Beardall A. Recurrent vulvovaginal candidiasis: why does it occur?. Int J STD AIDS 1999, 10:435. 10.1258/0956462991914429, 10454177.
18. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol 1993, 36:153. 10.1097/00003081-199303000-00021, 8435940.
19. Sobel JD. Vaginitis. NEJM 1896-1903, 1997:337.
20. Sobel JD. Vulvovaginal candidosis. Lancet 1961-1971, 2007:369.
21. Spacek J, Buchta V, Jilek P, Forstl M. Clinical aspects and luteal phase assessment in patients with recurrent vulvovaginal candidiasis. Eur J Obstet Gynecol Reprod Biol 2007, 131:198-202. 10.1016/j.ejogrb.2006.03.009, 16687200.
22. Sobel JD. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann NY Acad Sci 1988, 544:547-557. 10.1111/j.1749-6632.1988.tb40450.x, 3063184.
23. Rosa MI, Silva BR, Pires PS, Silva FR, Silva NC, Silva FR, Souza SL, Madeira K, Panatto AP, Medeiros LR. Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013, 167:132-136. 10.1016/j.ejogrb.2012.12.001, 23280281.
24. Zhou X, Westman R, Hickey R, Hansmann MA, Kennedy C, Osborn TW, Forney LJ. Vaginal microbiota of women with frequent vulvovaginal candidiasis. Infect Immun 2009, 77:4130-4135. 10.1128/IAI.00436-09, 2738030, 19528218.
25. Abdelmonem AM, Rasheed SM, Mohamed AS. Bee-honey and yogurt: a novel mixture for treating patients with vulvovaginal candidiasis during pregnancy. Arch Gynecol Obstet 2012, 386:109-114.
26. Wojitani MDKH, Aguiar LM, Baracat EC, Linhares IM. Association between mannose-binding lectin and interleukin-1 receptor antagonist gene polymorphisms and recurrent vulvovaginal candidiasis. Arch Gynecol Obstet 2011, 285:149-153.
27. Fan S, Liu X. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses 2011, 54:501-505. 10.1111/j.1439-0507.2010.01887.x, 20406393.
28. Liu W, Zhang X, Liu Z, Luo X. Impact of pH on the antifungal susceptibility of vaginal Candida albicans. Int J Gynecol Obstet 2011, 114:278-280.
29. Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F, Maazoun L, Khaled S, Khrouf S, Boujelben Y, Ayada A. Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses 2011, 54:e499-e505. 10.1111/j.1439-0507.2010.01965.x, 21039942.
30. González IDC, González FGB, Cuesta TS, Fernández JM, Rodríguez JMDA, Ferrairo RAE, Alonso MCDH, Arenas LB, Barrientos RR, Wiesmann EC, Romero CD, Diaz YG, Rodriguez-Monino A, Teira BG, del Pozo MS, Horcajuelo JF, Giraldo MJ, Gonzalez PC, Cuadrado RAV, Uriarte BL, Yepes JS, Sanz YH, Pineiro MJI, Hernandez ST, Alonso FG, Gonzalez AIG, Fernandez AS, Carballo C, Lopez AR, Morales F, Lopez DM., GRUPO PRESEVAC Patient preferences and treatment safety for uncomplicated vulvovaginal candidiasis in primary health care. BMC Public Health 2011, 11:63. 10.1186/1471-2458-11-63, 3048533, 21281464, GRUPO PRESEVAC.
31. Faro S, Faro S. New treatments for vulvovaginal candidiasis. Infect Dis Obstet Gynecol 1996, 4:247-254. 2364495, 18476101.
32. Sobel JD. Candida vulvovaginitis. UpToDate 2011, Waltham, MA: UpToDate, Basow DS.
33. Sobel JD. Vulvovaginitis. Female Sexual Pain Disorders: Evaluation and Management 2009, Hoboken, NJ, USA: Blackwell Publishing, Goldstein A, Pukall CF, Goldstein I.
34. Ehrström S, Yu A, Rylander E. Glucose in vaginal secretions before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol 2006, 108:1432. 10.1097/01.AOG.0000246800.38892.fc, 17138777.
35. Sobel J. Vulvovaginitis in healthy women. Compr Ther 1999, 25:335-346. 10.1007/BF02944280, 10470518.
36. Rylander E. Vulvovaginal candida in a young sexually active population: prevalence and association with oro-genital sex and frequent pain at intercourse. Sex Transm Infect 2004, 80:54-57. 10.1136/sti.2003.004192, 1758393, 14755037.
37. Walker PP. Vaginal yeasts in the era of " over the counter" antifungals. Sex Transm Infect 2000, 76:437-438. 10.1136/sti.76.6.437, 1744236, 11221124.
38. Sobel JD, Brooker D, Stein GE, Thomason JL, Wermeling DP, Bradley B, Weinstein L. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am J Obstet Gynecol 1995, 172:1263-1268. 10.1016/0002-9378(95)91490-0, 7726267.
39. Sawyer SM, Bowes G, Phelan PD. Vulvovaginal candidiasis in young women with cystic fibrosis. BMJ 1994, 308:1609. 10.1136/bmj.308.6944.1609, 2540404, 8025429.
40. Nelson AL. The impact of contraceptive methods on the onset of symptomatic vulvovaginal candidiasis within the menstrual cycle. Am J Obstet Gynecol 1997, 176:1376-1380. 10.1016/S0002-9378(97)70362-4, 9215201.
41. Mathema B, Cross E, Dun E, Park S, Bedell J, Slade B, Williams M, Riley L, Chaturvedi V, Perlin DS. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis 2001, 33:e23. 10.1086/322600, 11477529.
42. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004, 104(5, Part 1):926. 10.1097/01.AOG.0000140687.51048.73, 15516380.
43. Fidel PL, Lynch ME, Lopez VR, Sobel JD, Robinson R. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis 1993, 168:1458. 10.1093/infdis/168.6.1458, 8245529.
44. Patel DA, Gillespie B, Sobel JD, Leaman D, Nyirjesy P, Weitz MV, Foxman B. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: results of a prospective cohort study. Am J Obstet Gynecol 2004, 190:644-653. 10.1016/j.ajog.2003.11.027, 15041994.
45. Nyirjesy P. Chronic vulvovaginal candidiasis. Am Fam Physician 2001, 63:697.
46. Denning DW. Fortnightly review: Management of genital candidiasis. BMJ 1995, 310:1241-1244. 10.1136/bmj.310.6989.1241, 2549619, 7767196.
47. O'Neill S, Howard J. Recurrent vulvovaginal candidiasis. A gynaecological enigma. Aust Fam Physician 1989, 18:99.
48. Osser S, Haglund A, Weström L. Treatment of candidal vaginitis: A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. Acta Obstet Gynecol Scand 1991, 70:73-78. 10.3109/00016349109006182, 1858500.
49. Corson SL, Kapikian RR, Nehring R. Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison. J Reprod Med 1991, 36:561.
50. Sobel JD. Pathophysiology of vulvovaginal candidiasis. J Reprod Med 1989, 34(8 Suppl):572.
51. CDC Sexually transmitted diseases treatment guidelines, 2010. MMWR 2010, 59(RR12):1-110. CDC.
52. Mahmoudi Rad M, Zafarghandi AS, Amel Zabihi M, Tavallaee M, Mirdamadi Y. Identification of Candida species associated with vulvovaginal candidiasis by multiplex PCR. Infect Dis Obstet Gynecol 2012, 2012:1-5.
53. Amouri I, Sellami H, Abbes S, Hadrich I, Mahfoudh N, Makni H, Ayadi A. Microsatellite analysis of Candida isolates from recurrent vulvovaginal candidiasis. J Med Microb 2012, 61:1091-1096.
54. Pietrella D, Rachini A, Pines M, Pandey N, Mosci P, Bistoni F, d' Enfert C, Vecchiarelli A. Th17 Cells and IL-17 in protective immunity to vaginal candidiasis. PLoS One 2011, 6:e22770. 10.1371/journal.pone.0022770, 3144947, 21818387.
55. Köhler GA, Assefa S, Reid G. Probiotic interference of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 with the opportunistic fungal pathogen Candida albicans. Infect Dis Obstet Gynecol 2012, 2012:1-14.
56. Yano J, Kolls JK, Happel KI, Wormley F, Wozniak KL, Fidel PL. The acute neutrophil response mediated by S100 alarmins during vaginal Candida infections is independent of the Th17-pathway. PLoS One 2012, 7:e46311. 10.1371/journal.pone.0046311, 3457984, 23050010.
57. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am Fam Physician 2000, 61:3306.
58. Beikert FC, Le MT, Koeninger A, Technau K, Clad A. Recurrent vulvovaginal candidosis: focus on the vulva. Mycoses 2011, 54:e807-e810. 10.1111/j.1439-0507.2011.02030.x, 21615545.
59. Donders GGG, Mertens I, Bellen G, Pelckmans S. Self-elimination of risk factors for recurrent vaginal candidosis. Mycoses 2011, 54:39-45.
60. Mardh PA, Rodrigues AG, Genc M, Novikova N, Martinez-de-Oliveira J, Guaschino S. Facts and myths on recurrent vulvovaginal candidosis-a review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy. Int J STD AIDS 2002, 13:522-539. 10.1258/095646202760159639, 12194734.
61. Watson CJ, Pirotta M, Myers P. Use of complementary and alternative medicine in recurrent vulvovaginal candidiasis-Results of a practitioner survey. Complement Ther Med 2012, 20:218-221. 10.1016/j.ctim.2012.01.004, 22579433.
62. Shokri H, Khosravi AR, Yalfani R. Antifungal efficacy of propolis against fluconazole-resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis. Int J Gynecol Obstet 2011, 114:158-159.
63. Hurley R. Candidal vaginitis. Proc R Soc Med 1977, 70(Suppl 4):1.
64. Ajello L. The medical mycological iceberg. The Epidemiology of Human Mycotic Diseases 1975, 290. Springfield, Ill: Thomas, Al-Doory Y.
65. Hurley R, de Louvois J. Candida vaginitis. Postgrad Med J 1979, 55:645. 10.1136/pgmj.55.647.645, 2425644, 523355.
66. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis 1992, 14(Supplement 1):S148. 10.1093/clinids/14.Supplement_1.S148, 1562688.
67. Sobel JD. Management of patients with recurrent vulvovaginal candidiasis. Drugs 2003, 63:1059-1066. 10.2165/00003495-200363110-00002, 12749733.
68. Foxman B, Muraglia R, Dietz J-P, Sobel JD, Wagner J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: Results from an internet panel survey. J Lower Genital Tract Dis 2013, 17:340-345.
69. Berg AO, Heidrich FE, Fihn SD, Bergman JJ, Wood RW, Stamm WE, Holmes KK. Establishing the cause of genitourinary symptoms in women in a family practice. JAMA 1984, 251:620. 10.1001/jama.1984.03340290034016, 6690835.
70. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Pub Health 1990, 80:329.
71. Geiger A, Foxman B, Gillespie B. The epidemiology of vulvovaginal candidiasis among university students. Am J Pub Health 1995, 85(8 Pt 1):1146-1148.
72. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology 1996, 7:182-187. 10.1097/00001648-199603000-00013, 8834559.
73. Schaaf VM. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Internal Med 1929, 1990:150.
74. Odds FC. Candidosis of the genitalia. Candida and Candidosis 1988, 124-135. London, England: Bailliere Tindall, 2.
75. Ledger WJ, Monif GRG. A growing concern: Inability to diagnose vulvovaginal infections correctly. Obstet Gynecol 2004, 103:782-784. 10.1097/01.AOG.0000114988.61223.22, 15051575.
76. Nyirjesy P, Weitz MV, Grody MH, Lorber B. Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms. Obstet Gynecol 1997, 90:50-53. 10.1016/S0029-7844(97)00242-1, 9207812.
77. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 2002, 99:419-425. 10.1016/S0029-7844(01)01759-8, 11864668.
78. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009, 339:b2680. 10.1136/bmj.b2680, 2714656, 19622839.